"8"^^ . "8"^^ . . "high-dose chemotherapy;pediatric oncol\u016Fogy;methotrexate;homocysteine;folate;p53 functional activation"@en . "NC7104" . "Plasmatick\u00FD homocystein a funk\u010Dn\u00ED aktivace p53 jako mo\u017En\u00E9 markery \u00FA\u010Dinnosti vysokod\u00E1vkovan\u00E9ho methotrexatu u lymfoblastick\u00FDch malignit u d\u011Bt\u00ED" . "folate" . "definice skupiny pacient\u016F pl\u00E1novan\u00FDch ke sledov\u00E1n\u00ED plasmatick\u00FDch hladin homocystienu ze skupiny d\u011Bt\u00ED s diagnosami ALL. NHL, kter\u00E9 budou l\u00E9\u010Deny protokolem obsahuj\u00EDc\u00EDm high-dose MTX. stanoven\u00ED inici\u00E1ln\u00EDch hladin fol\u00E1tu vitam\u00EDnu B12 a homocysteinu a d\u00E1le sledov\u00E1n\u00ED profilu plasmatick\u00E9ho Hcys ve sch\u00E9matu: T12 - T24 (konce infuse) - T48 - T72 - T96 hodin anal\u00FDza zm\u011Bn exprese proteinu p53 v bu\u0148k\u00E1ch tumoru v odpov\u011B\u010F na induk\u010Dn\u00ED l\u00E9\u010Dbu pacienta s c\u00EDlem zjistit, zdali indukce funk\u010Dn\u00EDho p53 a p53 inducibiln\u00EDch protein\u016F charakterizuje skupinu na\u0161ich pacient\u016F vzhledem ke klinick\u00E9 odpov\u011Bdi na terapii. sledov\u00E1n\u00ED klinick\u00FDch a %22laboratorn\u00ED zn\u00E1mky \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby%22 (definovan\u00E9 pro tento \u00FA\u010Del jako m\u00EDra vzestupu homocysteinu po pod\u00E1n\u00ED MTX odr\u00E1\u017Eej\u00EDc\u00ED jeho antifol\u00E1tov\u00FD \u00FA\u010Dinek, a m\u00EDra funk\u010Dn\u00ED aktivace p53)" . . . . . . "methotrexate" . "0"^^ . "high-dose chemotherapy" . . . "1"^^ . . "1"^^ . "Korelace inici\u00E1ln\u00EDch hladin fol\u00E1t\u016F p\u0159ed pod\u00E1n\u00EDm methotrex\u00E1tu s v\u00FD\u0161\u00ED hladin MTX v krvi a s vzestupem homocysteinu umo\u017E\u0148uje vyslovit hypot\u00E9zu, \u017Ee plasmatick\u00E1 koncentrace homocysteinu je vhodn\u00FDm biomarkerem antifol\u00E1tov\u00E9ho \u00FA\u010Dinku methotrex\u00E1tu."@cs . . "to define a group of patients where homocysteine profiling will be conducted; based on preliminary data, where the dosage range 2-5 g/m2 of MTX was used, patients with lymphoproliferative diseases will be included to determine in these patients initial plasma levels of homocysteine, folate, cobalamin (time to before MTX infusion) and then plasma levels of homocysteine in the following time profile:To(hours - T12 - T24(end of MTX i.v. infusion) T48 - T72 and T96. to analyse induction of p53 protein in response to chemotherapy; to investigate whether induction of functional p53 and p53-inducible proteins reflects chemother\u010Dapy efficacy and relation to in vivo markers of folate metabilism to investigate the relation of MTX pharmacokinetics to homocysteine plasma profile AND to toxicities observed in an attempt to figure out potential of MTX dose individualization using markers of folate metabolism"@en . . "http://www.isvav.cz/projectDetail.do?rowId=NC7104"^^ . "2005-07-18+02:00"^^ . . . "pediatric oncol\u016Fogy" . "Plasma homocysteine and functional activation of p53 as putative markers of effect of high-dose methotrexate in lymphoblastic malignancies in children"@en . . . "Correlation of initial levels of folate with homocysteine levels before application of methotrexate rise a hypothesis, that plasmatic concentration of homocysteine can be valid biomarker of antifolate effects of methotrexate."@en . . . "homocysteine" . . . .